News & articles

June 2011 June’s American Society of Clinical Oncology (ASCO) conference in Chicago demonstrated that investments in MPN Research are starting to pay off as multiple drugs move through the drug development pipeline. Walking the halls of McCormick one could not help but be struck by strong notes of excitement and optimism. Discoveries related to melanoma,… Read More »MPN RESEARCH PAYS OFF AS NEW MPN DRUGS ADVANCE TO MARKET: A REPORT FROM ASCO

May 2011 The cluster of polycythemia vera that has been identified in the area surrounding a Superfund site in Pennsylvania has produced some questions on whether PV may be under-diagnosed. One investigator, Dr. Roda, has suggested that the prevalence of PV has been steady, but not diagnosed as widely as it is now that there… Read More »QUESTIONS REMAIN ON PENNSYLVANIA PV CLUSTER

Demanding a Recount: MPDs May Not Be as Rare as the Experts Think If you or someone you know has a Philadelphia Chromosome Negative Myeloproliferative Disorder (Polycythemia Vera, Essential Thrombocythemia or Chronic Idiopathic Myelofibrosis), you’ve probably been told it’s a rare or “orphan” disease, with one or two cases per 100,000 people. That has been… Read More »MPD FOUNDATION SPONSORS NEW EPIDEMIOLOGY STUDY

In 2006 Al Bolea passed away from myelofibrosis. As Al was an avid cycliest, each year since his friends and family have gathered to celebrade his life and raise money for MPN research by hosting a charity bicycle ride. The ride takes place near Boston and includes an after party with BBQ and a raffle. In… Read More »AL BOLEA MEMORIAL BIKE RIDE

In May 2010, the MPD Foundation hosted an educational symposium for over 100 patients and guests in San Mateo, California. The setting was beautiful and the venue, which was provided by Tano Corporation, was perfect for this event. Speakers included Drs. Ruben Mesa, Mayo Clinic, Arizona; Ayalew Tefferi, Mayo Clinic, Rochester; Jason Gotlib, Stanford; David… Read More »BAY AREA MPN SYMPOSIUM 2010

MPN patients can face financial hardships in addition to, or because of their diagnosis of ET, PV or MF. From the impact of having less energy to work full time, to wanting or needing to hire help with household tasks, to the high cost of copays or insurance, it can have a great financial toll… Read More »FINANCIAL ASSISTANCE FOR MPN PATIENTS

MPN Research Foundation visits Cancer Centers across the country to meet with their hematology groups to share information about the Foundation including the research we fund into the myeloproliferative neoplasms, educational symposia for myeloproliferative neoplasms patients, and brief updates on clinical trials for myeloproliferative neoplasms.  This program was created to engage hematologists and to ensure… Read More »MPN RESEARCH FOUNDATION INITIATES CANCER CENTER VISITS

Dear member of the MPN community, Each year when preparing this letter, the reality of our accomplishments and the progress in the entire MPN community leave us with a great sense of pride and renewed hope for the future.  Walking the Walk To date, the MPN Research Foundation has awarded over $8.2 million for medical… Read More »LETTER FROM OUR VICE PRESIDENT OF DEVELOPMENT

At the recent ASH meeting, pharmaceutical company Eli Lily announced findings from their Phase I trial for LY2784544, a JAK2 inhibitor. They are developing this compound for the treatment of patients with JAK2 positive polycythemia vera, essential thrombocythemia or myelofibrosis. For more information please click here to be redirected to Eli Lily’s press release.

By Dr. Claire HarrisonGuy’s and St. Thomas’ Hospital, London, UK  I was very pleased to be asked to write on this topic. Just as there are gender differences in other aspects of life; specific concerns arise for women who have MPNs. Some of my colleagues thought the idea was “sexist” or “biased” but most also… Read More »WOMEN AND MPNS